WO2024258870A8 - Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine - Google Patents

Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine

Info

Publication number
WO2024258870A8
WO2024258870A8 PCT/US2024/033443 US2024033443W WO2024258870A8 WO 2024258870 A8 WO2024258870 A8 WO 2024258870A8 US 2024033443 W US2024033443 W US 2024033443W WO 2024258870 A8 WO2024258870 A8 WO 2024258870A8
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
receptor agonist
beta receptor
agonist binding
lymphotoxin beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033443
Other languages
English (en)
Other versions
WO2024258870A2 (fr
Inventor
Rajkumar NOUBADE
Ian Nevin FOLTZ
Hong Yu Wang
Danyang GONG
Ryan Benjamin CASE
Jun Zhang
Chin-Wen Lai
Fernando Garces
Christine Elaine Tinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202480038870.XA priority Critical patent/CN121399157A/zh
Priority to EP24741027.7A priority patent/EP4724490A2/fr
Priority to IL325097A priority patent/IL325097A/en
Priority to AU2024305352A priority patent/AU2024305352A1/en
Priority to PE2025003091A priority patent/PE20260306A1/es
Priority to CR20260012A priority patent/CR20260012A/es
Priority to KR1020267000619A priority patent/KR20260025131A/ko
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of WO2024258870A2 publication Critical patent/WO2024258870A2/fr
Priority to JOJO/P/2025/0305A priority patent/JOP20250305A1/ar
Publication of WO2024258870A8 publication Critical patent/WO2024258870A8/fr
Anticipated expiration legal-status Critical
Priority to MX2025015224A priority patent/MX2025015224A/es
Priority to CONC2025/0018800A priority patent/CO2025018800A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2024/033443 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine Ceased WO2024258870A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020267000619A KR20260025131A (ko) 2023-06-12 2024-06-11 림포톡신 베타 수용체 작용제 결합 단백질
IL325097A IL325097A (en) 2023-06-12 2024-06-11 Lymphotoxin receptor agonist binding proteins
AU2024305352A AU2024305352A1 (en) 2023-06-12 2024-06-11 Lymphotoxin beta receptor agonist binding proteins
PE2025003091A PE20260306A1 (es) 2023-06-12 2024-06-11 Proteinas de union a receptor de linfotoxina beta agonistas
CR20260012A CR20260012A (es) 2023-06-12 2024-06-11 Proteínas de unión a receptor de linfotoxina beta agonistas
CN202480038870.XA CN121399157A (zh) 2023-06-12 2024-06-11 淋巴毒素β受体激动剂结合蛋白
EP24741027.7A EP4724490A2 (fr) 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
JOJO/P/2025/0305A JOP20250305A1 (ar) 2023-06-12 2025-12-11 البروتينات الرابطة المنشطة لمستقبل الليمفوتوكسين بيتا
MX2025015224A MX2025015224A (es) 2023-06-12 2025-12-15 Proteinas de union a receptor de linfotoxina beta agonistas
CONC2025/0018800A CO2025018800A2 (es) 2023-06-12 2025-12-24 Proteínas de union a agonistas del receptor de linfoxina beta

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472565P 2023-06-12 2023-06-12
US63/472,565 2023-06-12

Publications (2)

Publication Number Publication Date
WO2024258870A2 WO2024258870A2 (fr) 2024-12-19
WO2024258870A8 true WO2024258870A8 (fr) 2025-12-11

Family

ID=91899198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033443 Ceased WO2024258870A2 (fr) 2023-06-12 2024-06-11 Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine

Country Status (15)

Country Link
EP (1) EP4724490A2 (fr)
KR (1) KR20260025131A (fr)
CN (1) CN121399157A (fr)
AR (1) AR132931A1 (fr)
AU (1) AU2024305352A1 (fr)
CL (1) CL2025003919A1 (fr)
CO (1) CO2025018800A2 (fr)
CR (1) CR20260012A (fr)
IL (1) IL325097A (fr)
JO (1) JOP20250305A1 (fr)
MX (1) MX2025015224A (fr)
PE (1) PE20260306A1 (fr)
TW (1) TW202506733A (fr)
UY (1) UY40783A (fr)
WO (1) WO2024258870A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026122400A1 (fr) * 2024-12-03 2026-06-11 Amgen Inc. Protéines de liaison au récepteur b de lymphotoxine bispécifique

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR101115797B1 (ko) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
WO2007005612A2 (fr) 2005-07-01 2007-01-11 Medimmune, Inc. Approche integree permettant de generer des applications therapeutiques a base de proteine multidomaine
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
SG170091A1 (en) 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
WO2009077483A1 (fr) 2007-12-14 2009-06-25 Novo Nordisk A/S Anticorps humains anti-nkg2d et leurs utilisations
EA019595B1 (ru) 2007-04-17 2014-04-30 Имклоун Элэлси СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
AU2008275985B2 (en) 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
EP2236517A1 (fr) 2009-03-31 2010-10-06 Takara Bio, Inc. Anticorps monoclonal à fragment anti-fibronectine
CA2762720A1 (fr) 2009-05-21 2010-11-25 Tamarisk Technologies, L.L.C. Materiaux de construction a base d'alginate
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
CA2770174A1 (fr) 2009-08-31 2011-03-03 Roche Glycart Ag Anticorps monoclonaux anti-cea humanises obtenus par maturation d'affinite
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
JP5660486B2 (ja) 2010-02-12 2015-01-28 国立大学法人 鹿児島大学 ムチン１（ｍｕｃ１）タンパク質に対する抗体及びその用途
EP3904391B1 (fr) 2010-03-10 2024-07-10 Genmab A/S Anticorps monoclonaux contre c-met
KR20130108069A (ko) 2010-04-15 2013-10-02 알퍼 바이오테크, 엘엘씨 Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도
US8623369B2 (en) 2010-04-27 2014-01-07 National Research Council Of Canada Anti-ICAM-1 single domain antibody and uses thereof
WO2011139375A1 (fr) 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
JP2013534813A (ja) 2010-05-26 2013-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗ｃｄ１３３抗体一本鎖可変断片、及びこれらの使用
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
US8987423B2 (en) 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
KR20130048242A (ko) 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-종양 항원 항체 및 이용 방법
US20140093514A1 (en) 2011-06-03 2014-04-03 University Of Zurich Magea3 binding antibodies
CN107011439B (zh) 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用
EP2548891A1 (fr) 2011-07-18 2013-01-23 Universiteit Maastricht Anticorps monoclonal humain contre la subunité gamma du récepteur de l'acétylcholine pour une utilisation dans le traitement du rhabdomyosarcome
RU2015115956A (ru) 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
CN104884617B (zh) 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
CN105555804B (zh) 2013-08-07 2020-12-25 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
EP3143046B1 (fr) 2014-05-14 2020-06-17 F. Hoffmann-La Roche AG Protéines de liaison d'antigène her1 pour la liaison en épingle à cheveux bêta de her1
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3250611B1 (fr) 2015-01-26 2021-04-21 The University of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13r-alpha2 spécifique au cancer
US10711068B2 (en) 2015-03-26 2020-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD133 monoclonal antibodies and related compositions and methods
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
RU2018102526A (ru) 2015-06-24 2019-07-25 Еурека Терапьютикс, Инк. Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
CN109641954A (zh) 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
KR102531251B1 (ko) 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
WO2018069871A2 (fr) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Protéines de liaison anti-kras
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
JP2020534370A (ja) 2017-09-21 2020-11-26 ユーエムセー ユトレヒト ホールディング ベイフェイＵＭＣ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 神経芽腫の治療のための抗ｇｄ２抗体
WO2019084553A1 (fr) 2017-10-27 2019-05-02 New York University Anticorps anti-galectine-9 et leurs utilisations
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
BR112021002032A2 (pt) 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
AU2019359812A1 (en) 2018-10-15 2021-05-20 Board Of Regents, The University Of Texas System Monoclonal antibodies against human dickkopf3 and uses thereof
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途

Also Published As

Publication number Publication date
CR20260012A (es) 2026-03-09
PE20260306A1 (es) 2026-02-11
CO2025018800A2 (es) 2026-03-26
UY40783A (es) 2024-12-31
CL2025003919A1 (es) 2026-01-23
WO2024258870A2 (fr) 2024-12-19
KR20260025131A (ko) 2026-02-23
AR132931A1 (es) 2025-08-13
TW202506733A (zh) 2025-02-16
CN121399157A (zh) 2026-01-23
EP4724490A2 (fr) 2026-04-15
MX2025015224A (es) 2026-02-03
IL325097A (en) 2026-02-01
JOP20250305A1 (ar) 2025-12-11
AU2024305352A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
EP4212527A4 (fr) Composé agoniste du récepteur glp-1r et son utilisation
AU2024305352A1 (en) Lymphotoxin beta receptor agonist binding proteins
EP4095149A4 (fr) Triple agoniste pour récepteur du peptide-1 type glucagon, récepteur du glucagon, et récepteur du polypeptide inhibiteur gastrique
EP4019524A4 (fr) Composé agoniste du récepteur thr-bêta hétérocyclique, son procédé de préparation et son utilisation
MA55529A (fr) Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
CA3265218A1 (fr) Protéines de fusion de récepteurs de lymphocytes t spécifiques de mage a4
EP4159722A4 (fr) Procédé de préparation d'agoniste du récepteur glp-1
SI2197900T1 (sl) Mutantni dvojno ciklizirani receptorski peptidi ki inhibirajo protitelesa beta adrenoceptorja
CA3295009A1 (fr) Protéines de liaison à un agoniste du récepteur bêta de la lymphotoxine
EP4144757A4 (fr) Agoniste double du récepteur du glp-1 et du glucagon à action prolongée
AU2024362819A1 (en) Transferrin receptor binding proteins and uses thereof
CA3267339A1 (fr) Anticorps agonistes de pd-1
HK40106103A (en) Thyroid hormone receptor beta agonist compounds
CA3275875A1 (fr) Protéines de liaison au récepteur de la transferrine
HK40131944A (en) Transferrin receptor binding proteins
HK40074189A (en) Thyroid hormone receptor beta agonist compounds
CA3296481A1 (fr) Polythérapie avec des agonistes du récepteur bêta de la lymphotoxine ciblant fap
CA3276371A1 (fr) Agonistes du récepteur de la galanine-2
AU2021901129A0 (en) Antigen binding proteins for binding dysfunctional P2X7 receptor
CA3275190A1 (fr) Formulations d'agoniste de récepteur d'hormone inhalable
HK40108078A (en) Fusion protein containing improved glp-1 receptor agonist and uses
HK40108106A (en) Polymorph as thyroid hormone receptor agonists and use thereof
HK40122612A (en) Glucocorticoid receptor agonists
HK40055638A (en) Thyroid hormone receptor beta agonist compounds
HK40120463A (en) T cell receptor fusion proteins specific for mage a4

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24741027

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: AU2024305352

Country of ref document: AU

Ref document number: 827438

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 827438

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 325097

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2024305352

Country of ref document: AU

Date of ref document: 20240611

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2025571621

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: CN202480038870X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: P2025-04030

Country of ref document: AE

WWE Wipo information: entry into national phase

Ref document number: 2501008501

Country of ref document: TH

Ref document number: 202517125869

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/015224

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025027542

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: DZP2025001884

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 202593502

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 202517125869

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 325097

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 1020267000619

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: 1020267000619

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: CR2026-000012

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWE Wipo information: entry into national phase

Ref document number: 2024741027

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWE Wipo information: entry into national phase

Ref document number: 11202508343V

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202508343V

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWP Wipo information: published in national office

Ref document number: MX/A/2025/015224

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024741027

Country of ref document: EP

Effective date: 20260112

WWP Wipo information: published in national office

Ref document number: 1020267000619

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: CR2026-000012

Country of ref document: CR

WWP Wipo information: published in national office

Ref document number: 2024741027

Country of ref document: EP